Cargando…
Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome
Clinical trials have demonstrated that lonafarnib, a farnesyltransferase inhibitor, extends the lifespan in patients afflicted by Hutchinson-Gilford progeria syndrome, a devastating condition that accelerates many characteristics of aging and results in premature death due to cardiovascular sequelae...
Autores principales: | Murtada, Sae-Il, Mikush, Nicole, Wang, Mo, Ren, Pengwei, Kawamura, Yuki, Ramachandra, Abhay B, Li, David S, Braddock, Demetrios T, Tellides, George, Gordon, Leslie B, Humphrey, Jay D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023154/ https://www.ncbi.nlm.nih.gov/pubmed/36930696 http://dx.doi.org/10.7554/eLife.82728 |
Ejemplares similares
-
Hutchinson-Gilford progeria syndrome
por: Bhukya, Amar Singh, et al.
Publicado: (2015) -
Lonafarnib and everolimus reduce pathology in iPSC-derived tissue engineered blood vessel model of Hutchinson-Gilford Progeria Syndrome
por: Abutaleb, Nadia O., et al.
Publicado: (2023) -
Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype
por: Gabriel, Diana, et al.
Publicado: (2016) -
Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome
por: Díez-Díez, Miriam, et al.
Publicado: (2022) -
Sulforaphane enhances progerin clearance in Hutchinson–Gilford progeria fibroblasts
por: Gabriel, Diana, et al.
Publicado: (2015)